GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InterMune Inc (FRA:IUX) » Definitions » E10

InterMune (FRA:IUX) E10 : €-1.56 (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is InterMune E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

InterMune's adjusted earnings per share data for the three months ended in Jun. 2014 was €-0.530. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.56 for the trailing ten years ended in Jun. 2014.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-16), InterMune's current stock price is €58.06. InterMune's E10 for the quarter that ended in Jun. 2014 was €-1.56. InterMune's Shiller PE Ratio of today is .


InterMune E10 Historical Data

The historical data trend for InterMune's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InterMune E10 Chart

InterMune Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.72 -1.34 -1.68 -1.52 -1.55

InterMune Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.57 -1.56 -1.55 -1.55 -1.56

Competitive Comparison of InterMune's E10

For the Biotechnology subindustry, InterMune's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InterMune's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InterMune's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where InterMune's Shiller PE Ratio falls into.



InterMune E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, InterMune's adjusted earnings per share data for the three months ended in Jun. 2014 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2014 (Change)*Current CPI (Jun. 2014)
=-0.53/100.5595*100.5595
=-0.530

Current CPI (Jun. 2014) = 100.5595.

InterMune Quarterly Data

per share eps CPI Adj_EPS
200409 -0.327 80.121 -0.410
200412 -0.521 80.290 -0.653
200503 -0.409 81.555 -0.504
200506 -0.609 82.062 -0.746
200509 -0.605 83.876 -0.725
200512 1.552 83.032 1.880
200603 -0.324 84.298 -0.387
200606 -1.051 85.606 -1.235
200609 -0.692 85.606 -0.813
200612 -0.473 85.142 -0.559
200703 -0.461 86.640 -0.535
200706 -0.432 87.906 -0.494
200709 -0.475 87.964 -0.543
200712 -0.458 88.616 -0.520
200803 -0.483 90.090 -0.539
200806 -0.489 92.320 -0.533
200809 -0.223 92.307 -0.243
200812 -0.778 88.697 -0.882
200903 -0.789 89.744 -0.884
200906 -0.578 91.003 -0.639
200909 -0.130 91.120 -0.143
200912 -0.427 91.111 -0.471
201003 -0.486 91.821 -0.532
201006 -0.376 91.962 -0.411
201009 -0.336 92.162 -0.367
201012 1.861 92.474 2.024
201103 -0.406 94.283 -0.433
201106 -0.472 95.235 -0.498
201109 -0.458 95.727 -0.481
201112 -0.524 95.213 -0.553
201203 -0.545 96.783 -0.566
201206 -0.112 96.819 -0.116
201209 -0.489 97.633 -0.504
201212 -0.616 96.871 -0.639
201303 -0.517 98.209 -0.529
201306 -0.584 98.518 -0.596
201309 -0.456 98.790 -0.464
201312 -0.486 98.326 -0.497
201403 -0.427 99.695 -0.431
201406 -0.530 100.560 -0.530

Add all the adjusted EPS together and divide 10 will get our e10.


InterMune  (FRA:IUX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


InterMune E10 Related Terms

Thank you for viewing the detailed overview of InterMune's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


InterMune (FRA:IUX) Business Description

Traded in Other Exchanges
N/A
Address
InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.

InterMune (FRA:IUX) Headlines

No Headlines